KDA Group Announces the Appointments of Sylvain Duvernay as Chief Executive Officer and Pierre Monet as Chief Financial Officer

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)

  

Thetford Mines, Quebec TheNewswire - October 15, 2020 KDA Group Inc. (TSXV:KDA) (“KDA” or the “Corporation”) is pleased to announce today the appointments of Mr. Sylvain Duvernay as Chief Executive Officer of KDA and Mr. Pierre Monet as Chief Financial Officer of the Corporation, effective immediately.

Sylvain Duvernay – Mr. Duvernay holds a Bachelor’s degree in Business Administration and a Certificate in International Trade. He has over 20 years of experience in pharmaceutical and international business.

Mr. Duvernay filled the position of Vice-President for Strides Arcolab Ltd a pharmaceutical generic product company involved in softgel, injectable and solid dose manufacturing. He led its Canadian operations as well as its business development in the United States.

In 2008, Sylvain was behind the acquisition of the Bristol-Myers Squibb facility in Candiac where he developed a business model for the injectable business and acted as CEO of the new entity, Uman Pharma Inc.

The company was sold to Pharmascience in November 2014 and for two years, Sylvain was Vice-President, Injectable Products and responsible for the U.S. market, before moving to Capcium, a softgel manufacturing company for the pharmaceutical and nutraceutical sectors.

As Capcium’s CEO, he led the strategy and the construction of a state-of-the-art facility that will meet FDA, EMA and Health Canada standards.

Pierre Monet – Mr. Monet has more than 35 years’ experience in public and private companies at national and international levels. He has a solid background in finance combined with operations management.

He has played key roles in mergers and acquisitions as well as corporate restructuring. He has a strategic and results-oriented mind.

Mr. Monet holds a Bachelor’s degree in Business Administration from the Hautes Études Commerciales and is a Chartered Professional Accountant (CPA).

The Corporation’s current Chief Executive Officer, Mr. Marc Lemieux, will remain Chairman of the Board and Director, while the current Chief Financial Officer, Mrs. Annie Mercier, will now assume the role of Controller of KDA. The Board of Directors would like to thank Mr. Lemieux and Mrs. Mercier for all their loyal service over the years and good continuation within the Corporation.

“We are very proud to welcome Sylvain and Pierre to our management team. We are at an important juncture for the growth and implementation of the Corporation’s strategic plan. After having worked with Sylvain for several months as a member of the advisory committee, he was the key person to take over the position of Chief Executive Officer of KDA. With my support and my role as Chairman of the Board, I will be at his side to continue and pursue the Corporation’s success. Welcome to the KDA family,” said Marc Lemieux, Chairman of KDA’s Board of Directors.

“In addition, I am proud to introduce Pierre as KDA’s Chief Financial Officer, who will bring many years of experience to the management team and ensure the implementation of the new financial structure. The arrival of Messrs. Duvernay and Monet marks the beginning of a new era for KDA’s growth,” added Mr. Lemieux.

 

ABOUT KDA GROUP

KDA Group is a leading innovation and specialized solution provider in the pharmaceutical market. Today, it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical and medical sector. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.

 

- 30 -

 

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

 

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

 

INFORMATION

Marc Lemieux

Chief Executive Officer

514 622-7370

[email protected]

 

Copyright (c) 2020 TheNewswire - All rights reserved.